J&J will pay more than $2.2 billion to settle US cases

Bloomberg, November 5, 2013
Johnson & Johnson agreed to resolve criminal and civil probes into the marketing of Risperdal, an antipsychotic drug, and other medicines by paying more than $2.2 billion, one of the largest U.S. health-fraud penalties. J&J's Janssen unit will plead guilty to a misdemeanor criminal charge over misbranding Risperdal for uses not approved by the Food and Drug Administration, including treating elderly patients with dementia. Under a plea agreement announced today, Janssen will pay a $334 million fine and forfeit $66 million.

MOST POPULAR

" style="font-family:inherit">Physician's Scathing Remarks Humiliate Patient, Cost Hospital
  • Alternative Staffing Arrangements
  • " style="font-family:inherit">The Perils of Cut-and-Paste Documentation
  • Aging Doctors: Time for Mandatory Competency Testing?
  • 7 Years In, Triple Aim Transcends Jargon
  • Alternative Staffing Arrangements
  • CMS Predictive Readmission Models 'Not Very Good'
  • SPONSORED REPORTS
    SPONSORED HEADLINES

    SIGN UP

    FREE e-Newsletters Join the Council Subscribe to HL magazine

    SPONSORSHIP & ADVERTISING

    100 Winners Circle Suite 300
    Brentwood, TN 37027

    800-727-5257

    About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
    © HealthLeaders Media 2014 a division of BLR All rights reserved.